|Product Name:||Sunifiram||Other Name:||1-(4-Benzoyl-1-piperazinyl)-1-propanone|
|Shelf Life:||2 Years||Application:||Pharmaceutical API|
|Sample:||Available||Storage:||Cool And Dry Place|
Api Pharmaceutical Ingredients 314728 85 3,
Sunifiram Powder 314728 85 3,
Sunifiram Powder Api Pharmaceutical Ingredients
Pharmaceutical API White Solid Nootropics Powder CAS 314728-85-3 Sunifiram
|Boiling point||442.0±38.0 °C(Predicted)|
|Density||1.154±0.06 g/cm3 (20 ºC 760 Torr)|
|Acidity coefficient (pKa)||0.08±0.70(Predicted)|
Sunifiram (DM235) is a piperazine derived ampakine drug which acts as a positive allosteric modulator of AMPA receptors, and has nootropic effects in animal studies with significantly higher potency thanpiracetam. A number of related compounds are known, the best known being unifiram (DM-232).
This enhancement by sunifiram is associated with an increase inphosphorylation of AMPAR through activation of protein kinase II(CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). More specifically, sunifiram stimulates the glycinebinding site of NMDAR with concomitant PKCαactivation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation. Sunifiram improves cognitive deficits via CaM kinase II andprotein kinase C activation.
Contact Person: kate